Andrew Stewart Plump - 02 Sep 2026 Form 4 Insider Report for TAKEDA PHARMACEUTICAL CO LTD (TAK)

Reporting relationship: President, R&D, Director
Issuer ticker: TAK
Reported as of: 02 Sep 2026
Net transaction value: -$2,148,372
SEC form: 4
Accepted by SEC: 03 Sep 2026, 21:49:19 UTC
Prior SEC filing: 21 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ Kate Huleatt, by power of attorney, for Andrew Plump

Key filing fact

Andrew Stewart Plump filed Form 4 for TAKEDA PHARMACEUTICAL CO LTD (TAK) on 03 Sep 2026.

Key facts

This page summarizes Andrew Stewart Plump's Form 4 filing for TAKEDA PHARMACEUTICAL CO LTD (TAK).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 03 Sep 2026, 21:49.

Change

Previous filing in this sequence was filed on 21 Aug 2026.
Current net transaction value: -$2,148,372.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001977689 Primary reporting owner

Plump Andrew Stewart

Relationship: President, R&D, Director
Address: 300 MASSACHUSETTS AVE., CAMBRIDGE
Signature: /s/ Kate Huleatt, by power of attorney, for Andrew Plump
Signature date: 03 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TAK transaction

American Depositary Shares

Sale

Transaction value: $2,148,372
Shares: -116,191
Change %: -44%
Price: $18.49
Shares after: 145,465
Date: 02 Sep 2026
Ownership: By Trust
Footnotes: F1

TAK holding

American Depositary Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 766,569
Date: 02 Sep 2026
Ownership: Direct

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 1 footnote

Footnote F1

The sales reported herein were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on May 15, 2026.